MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Weak Balance Sheet

MRK's financial position is not ideal. The key is to check whether MRK is using debt to fuel its growth and the sustainability of that tendency. Highly capital intensive businesses (see Economic Moat) follow this route, which can deeply impact the future prospects of the business.
Figures in USD. Fiscal year ends in December
Cash 5.49B 9.60B 12.20B 14.97B 16.14B 17.49B 15.72B 13.43B 14.34B 8.50B
Current Assets 19.30B 28.43B 29.06B 33.18B 34.86B 35.69B 33.17B 29.76B 30.61B 24.77B
Total Assets 47.20B 112.09B 105.78B 105.13B 106.13B 105.65B 98.34B 101.78B 95.38B 87.87B
Current Liabilities 14.32B 15.75B 15.64B 16.25B 18.35B 17.87B 18.77B 19.20B 17.20B 18.61B
Total Liabilities 28.44B 53.03B 51.41B 50.61B 53.11B 55.88B 49.69B 57.10B 55.29B 53.54B
Stockholder' Equity 18.76B 59.06B 54.38B 54.52B 53.02B 49.77B 48.65B 44.68B 40.09B 34.34B
Current Ratio 1.35 1.80 1.86 2.04 1.90 2.00 1.77 1.55 1.78 1.33
TL-to-TA 0.60 0.47 0.49 0.48 0.50 0.53 0.51 0.56 0.58 0.61

Low or No Reinvestment of Profits over the past 10 years

MRK has either been retaining a small amount of their earnings or has done so inconsistently. A lack of consistency could be due to MRK operating at a loss or them having such a strong economic moat they feel comfortable spending profits on growth. Be wary of future prospects and if applicable, inspect the moat's sustainability.
Figures in USD. Fiscal year ends in December
Retained Earnings 43.70B 41.40B 37.54B 38.99B 39.99B 39.26B 46.02B 45.35B 44.13B 41.35B
Retained Earnings Growth - -5.25% -9.34% 3.87% 2.55% -1.82% 17.23% -1.46% -2.68% -6.31%